Cellumed Co

Cellumed Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Cellumed Co (049180.KQ) as of Oct 28, 2026 is 2.78 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -40.92 % — a change of -106.81% (higher).

EBIT/Assets

2.78 %

YoY

-106.81%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Cellumed Co is 2025 2.78 % . Operating Income to Assets Ratio (EBIT/Assets) of Cellumed Co was 2024 -40.92 % . It decreases by -106.81% higher compared to the previous year.

The Cellumed Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-25.11 KRW
Jan 1, 2019
-56.40 KRW
Jan 1, 2020
3.03 KRW
Jan 1, 2021
8.45 KRW
Jan 1, 2022
-1.45 KRW
Jan 1, 2023
-38.47 KRW
Jan 1, 2024
-40.92 KRW
Jan 1, 2025
2.78 KRW
The Cellumed Co EBIT/Assets history
YEAREBIT/AssetsYoY
2.78 %-106.81%
-40.92 %+6.37%
-38.47 %+2,556.43%
-1.45 %-117.14%
8.45 %+178.68%
3.03 %-105.37%
-56.40 %+124.64%
-25.11 %+1,646.41%
-1.44 %-93.57%
-22.36 %+121.20%
-10.11 %-37.89%
-16.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellumed Co Stock analysis

What does Cellumed Co do? Cellumed Co Ltd manufactures and distributes medical devices and biomaterials, including allografts for tissue repair, bone sponges, bone powders, and demineralized bone matrixes (DBMs) for bone regeneration. The company also produces biosimilars like bone morphogenetic protein 2 (BMP2) reagents and medical devices such as spinal fixation systems, joint replacements, and navigation systems. Cellumed sells these products domestically in Seoul and internationally to overseas markets. Cellumed’s primary customers are healthcare providers and medical institutions that require tissue repair solutions, bone regeneration products, and advanced medical devices. The company’s product portfolio targets orthopedic and spinal care segments, with a focus on biomaterials and surgical tools. Its biosimilars, including BMP2 reagents, cater to specialized medical applications requiring bone growth stimulation. The company generates revenue through direct sales of its medical devices and biomaterials to hospitals, clinics, and international distributors. Cellumed’s domestic market in Seoul serves local healthcare facilities, while its overseas sales expand its reach to global medical markets. The firm’s product range supports both routine and complex surgical procedures in orthopedics and spinal care. Cellumed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellumed Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Cellumed Co is 2.78 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Cellumed Co changed from -40.92 % to 2.78 %, representing a -106.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Cellumed Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Cellumed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cellumed Co

All Key Metrics — Cellumed Co